Developer docs
API playgroundTry for free, no card

Search company profiles

Madrigal Pharmaceuticals

Full company profile

uuid00009nw

Namestring
Madrigal Pharmaceuticals
Legal namestring
Madrigal Pharmaceuticals, Inc.
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Madrigal Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company (NASDAQ: MDGL) headquartered in Conshohocken, Pennsylvania, that develops and commercializes therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and related cardiovascular-metabolic diseases. Founded in 2008 by Rebecca Taub, M.D. and IPO'd on NASDAQ in 2016, the company spent the bulk of its pre-commercial history advancing a single liver-directed, oral, once-daily, beta-selective thyroid hormone receptor (THR-β) agonist — resmetirom — through Phase 1 (2011), Phase 2 (2016–2018), and the pivotal Phase 3 MAESTRO-NASH trial (initiated 2019, topline 2022). Resmetirom was approved by the FDA in March 2024 under accelerated approval and commercialized in the U.S. as Rezdiffra starting April 2024, followed by European Commission conditional marketing authorization in August 2025 and launch in Germany in September 2025. Rezdiffra remains the first and only approved therapy for MASH with moderate to advanced liver fibrosis (F2-F3) in both the U.S. and EU, with intellectual property protection extending to 2045.

Madrigal's commercial offering is anchored on Rezdiffra and supported by an integrated patient and physician services stack: the Madrigal Patient Support® program (copay assistance, affordability, education), Madrigal Medical/Madrigal Medical Affairs (HCP education at madrigalmedical.com, Defuse MASH and Melody platforms), the Taking on Fatty Liver & MASH patient-education site, and the Be Your Liver's #1 Fan awareness campaign. Distribution is handled through a specialty pharmaceutical sales force targeting hepatologists and liver specialists, with country-specific operations in Germany, Italy, Spain, the U.K., and a Swiss international headquarters. The company is actively building a combination MASH pipeline, having in-licensed an oral GLP-1 (CSPC, July 2025), a DGAT-2 inhibitor plus two MASH assets (Pfizer's ervogastat, January 2026), six preclinical siRNA programs (Ribo/Ribocure, February 2026), and the ARO-PNPLA3 siRNA asset (Arrowhead, May 2026), bringing the pipeline to more than 10 programs designed to be combined with or extend Rezdiffra.

Madrigal generates revenue almost entirely from Rezdiffra net product sales (FY2025: $958.4M, +432% YoY) at a 93% gross profit margin, with quarterly cadence demonstrating continued growth (Q4 2025: $321.1M, +211% YoY; Q1 2026: $311.3M, +127% YoY). The company has funded operations through a combination of post-IPO equity raises ($159M in 2022, $500M in 2023, $690M in 2024) and a $500M senior secured credit facility from Blue Owl Capital in July 2025. Pricing is not publicly disclosed but is supported by a copay-assistance and patient-access infrastructure. Leadership is led by CEO Bill Sibold (joined September 2023, ex-Sanofi EVP Specialty Care), CMO David Soergel (ex-Novartis cardiovascular/metabolism development head), CFO Mardi Dier, and a Baker Bros.-anchored board with Chairman Julian C. Baker.

Short descriptiontext

Madrigal Pharmaceuticals is a biopharmaceutical company developing and commercializing resmetirom (Rezdiffra), the first FDA- and EU-approved oral THR-β agonist for adults with MASH with moderate to advanced liver fibrosis. It sells via a specialty sales force in the U.S. and select EU markets while building a combination MASH pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersConshohocken, United States
HQ citystring
Conshohocken
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
MASH therapeutics, liver fibrosis treatment, specialty biopharmaceuticals, metabolic disease drugs, thyroid receptor agonist
Industry3 codes
PRIMARYHLAIAIAL
Rare Gastroenterology & Hepatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Biopharmaceuticals / Metabolic Liver Disease Therapeutics
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model2 records
1Rezdiffra (resmetirom) net product sales
TypeHardware Sales
Description

Primary revenue stream from commercial sales of Rezdiffra, the first FDA- and European Commission-approved treatment for MASH with moderate to advanced fibrosis. Full-year 2025 net sales reached $958.4 million, with Q4 2025 net sales of $321.1 million (up 211% YoY) and Q1 2026 net sales of $311.3 million (up 127% YoY). Generated at 93% gross profit margin. Rezdiffra launched in Germany in September 2025 following EU conditional marketing authorization.

biospace.com
2MASH pipeline licensing/milestone economics
TypeLicensing Royalties
Description

Future revenue potential from in-licensed pipeline assets including milestone payments and royalties tied to development progress of siRNA programs (Ribo), ARO-PNPLA3 (Arrowhead), ervogastat (Pfizer), and MGL-2086 (CSPC); however, these are primarily expense/investment items rather than near-term revenue.

madrigalpharma.com
Cost components5 values
Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain
Pricing details1 tier
1Statutory price transparency disclosures published for Colorado, Connecticut, and Vermont prescribers.
ModelUnit Pricing
Notes

Pricing is not publicly disclosed on the website; price transparency forms are provided per state law for Colorado, Connecticut, and Vermont. Copay assistance and patient access programs are offered through Madrigal Patient Support.

madrigalpharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Rezdiffra
Description

FDA- and European Commission-approved oral THR-β agonist (resmetirom) for the treatment of MASH with moderate to advanced liver fibrosis; the company's first and only approved product.

madrigalpharma.com
+2 more records
Core offering1 text field

Madrigal Pharmaceuticals develops and commercializes Rezdiffra (resmetirom), an oral, once-daily, liver-directed small-molecule selective thyroid hormone receptor-beta (THR-β) agonist that is the first U.S. FDA- and European Commission-approved treatment for adults with MASH (formerly NASH) with moderate to advanced liver fibrosis (F2-F3). The company is building a MASH combination-therapy pipeline that layers THR-β agonism with in-licensed mechanisms including siRNA gene-silencing (Arrowhead, Ribo), DGAT-2 inhibition (Pfizer's ervogastat), and oral GLP-1 receptor agonism (CSPC's MGL-2086).

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Madrigal Pharmaceuticals is a biopharmaceutical company whose commercial offering centers on a single integrated product portfolio anchored by Rezdiffra (resmetirom), the first U.S. FDA- and European Commission-approved oral THR-β agonist treatment for adults with MASH (formerly NASH) with moderate to advanced liver fibrosis. Rezdiffra is the only approved therapy in this indication in both the U.S. and EU and is supported by a layered commercial architecture comprising the Madrigal Patient Support® program (affordability, copay assistance, and education for patients), the Madrigal Medical / Madrigal Medical Affairs platform for healthcare professionals (madrigalmedical.com and the Defuse MASH and Melody education sites), the Taking on Fatty Liver & MASH patient-education site, and the Be Your Liver's #1 Fan awareness campaign. The product is currently positioned as a single approved product plus pipeline, but the company has executed multiple in-licensing deals (ervogastat from Pfizer, ARO-PNPLA3 from Arrowhead, MGL-2086 from CSPC, and six siRNA programs from Ribo/Ribocure) and is actively building a combination-therapy pipeline — including ervogastat/resmetirom, ARO-PNPLA3/resmetirom, MGL-2086/resmetirom, and siRNA/resmetirom combination candidates — designed to be paired with Rezdiffra to address the full spectrum of MASH patient needs.

Product and service2 records
1Rezdiffra (resmetirom)
CategoryCore pharmaceutical product (approved)
Description

Oral, once-daily, liver-directed, small-molecule selective thyroid hormone receptor-beta (THR-β) agonist. The first U.S. FDA- and European Commission-approved treatment for adults with MASH (formerly NASH) with moderate to advanced liver fibrosis (F2-F3). Approved under accelerated approval based on improvement of MASH and fibrosis. Full-year 2025 net sales reached $958.4 million, generated at 93% gross profit margin.

2Madrigal Patient Support®
CategoryPatient support program
Description

Registered-trademark patient support program offering copay assistance, affordability programs for uninsured/underinsured patients, and patient education to support patients on Rezdiffra throughout their treatment journey.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Pharma incumbent with tirzepatide (Mounjaro/Zepbound) and retatrutide in MASH development; large market cap and commercial scale pose a major competitive threat to Madrigal's specialty positioning.

TypeDirect peer
Description

MASH-focused biopharma developing pegozafermin (FGF21 analog) with Phase 3 ENLIGHTEN program; competes head-to-head with Rezdiffra in moderate-to-advanced MASH fibrosis.

TypeDirect peer
Description

Clinical-stage biopharma developing VK2809, an oral THR-β agonist for MASH in the same mechanism class as resmetirom, plus an oral GLP-1/GIP dual agonist. The closest mechanistic competitor to Madrigal's core asset and pipeline.

TypeDirect peer
Description

Late-stage MASH-focused biopharma developing efruxifermin (FGF21 analog) with Phase 3 HARMONY data; directly competing for share of the F2/F3 MASH market that Rezdiffra currently leads.

TypeEmerging player
Description

Late-stage MASH-focused biopharma developing lanifibranor (pan-PPAR agonist); competes in the same F2/F3 MASH regulatory pathway as Rezdiffra.

TypeOthers
Description

siRNA platform company that licensed ARO-PNPLA3 to Madrigal for combination development; a platform/licensing partner and emerging liver-targeted RNAi competitor.

TypeOthers
Description

Global pharma that licensed ervogastat (DGAT-2 inhibitor) to Madrigal in January 2026; remains a strategic licensor rather than direct MASH competitor following its exit from primary MASH development.

TypeBroad incumbent
Description

Global diabetes/obesity leader with semaglutide (Wegovy/Ozempic) advancing in MASH Phase 3 (ESSENCE); could reshape standard of care and pressure Rezdiffra positioning with massive commercial reach.

TypeEmerging player
Description

Developing TERN-501, an oral THR-β agonist for MASH, plus TERN-601 oral GLP-1 — a direct mechanism overlap with both Madrigal's resmetirom and its CSPC-licensed GLP-1 program.

10Bristol-Myers Squibb
TypeBroad incumbent
Description

Large-cap pharma with historic hepatology franchise (via Celgene) and ongoing cardiometabolic R&D; comparable specialty-care commercial organization and an experienced international footprint that overlaps Madrigal's launch geographies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Madrigal Pharmaceuticals

Specialty Biopharmaceuticals / Metabolic Liver Disease Therapeuticsmadrigalpharma.com

Madrigal Pharmaceuticals is a biopharmaceutical company developing and commercializing resmetirom (Rezdiffra), the first FDA- and EU-approved oral THR-β agonist for adults with MASH with moderate to advanced liver fibrosis. It sells via a specialty sales force in the U.S. and select EU markets while building a combination MASH pipeline.

What Madrigal Pharmaceuticals does

Madrigal Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company (NASDAQ: MDGL) headquartered in Conshohocken, Pennsylvania, that develops and commercializes therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and related cardiovascular-metabolic diseases. Founded in 2008 by Rebecca Taub, M.D. and IPO'd on NASDAQ in 2016, the company spent the bulk of its pre-commercial history advancing a single liver-directed, oral, once-daily, beta-selective thyroid hormone receptor (THR-β) agonist — resmetirom — through Phase 1 (2011), Phase 2 (2016–2018), and the pivotal Phase 3 MAESTRO-NASH trial (initiated 2019, topline 2022). Resmetirom was approved by the FDA in March 2024 under accelerated approval and commercialized in the U.S. as Rezdiffra starting April 2024, followed by European Commission conditional marketing authorization in August 2025 and launch in Germany in September 2025. Rezdiffra remains the first and only approved therapy for MASH with moderate to advanced liver fibrosis (F2-F3) in both the U.S. and EU, with intellectual property protection extending to 2045.

Madrigal's commercial offering is anchored on Rezdiffra and supported by an integrated patient and physician services stack: the Madrigal Patient Support® program (copay assistance, affordability, education), Madrigal Medical/Madrigal Medical Affairs (HCP education at madrigalmedical.com, Defuse MASH and Melody platforms), the Taking on Fatty Liver & MASH patient-education site, and the Be Your Liver's #1 Fan awareness campaign. Distribution is handled through a specialty pharmaceutical sales force targeting hepatologists and liver specialists, with country-specific operations in Germany, Italy, Spain, the U.K., and a Swiss international headquarters. The company is actively building a combination MASH pipeline, having in-licensed an oral GLP-1 (CSPC, July 2025), a DGAT-2 inhibitor plus two MASH assets (Pfizer's ervogastat, January 2026), six preclinical siRNA programs (Ribo/Ribocure, February 2026), and the ARO-PNPLA3 siRNA asset (Arrowhead, May 2026), bringing the pipeline to more than 10 programs designed to be combined with or extend Rezdiffra.

Madrigal generates revenue almost entirely from Rezdiffra net product sales (FY2025: $958.4M, +432% YoY) at a 93% gross profit margin, with quarterly cadence demonstrating continued growth (Q4 2025: $321.1M, +211% YoY; Q1 2026: $311.3M, +127% YoY). The company has funded operations through a combination of post-IPO equity raises ($159M in 2022, $500M in 2023, $690M in 2024) and a $500M senior secured credit facility from Blue Owl Capital in July 2025. Pricing is not publicly disclosed but is supported by a copay-assistance and patient-access infrastructure. Leadership is led by CEO Bill Sibold (joined September 2023, ex-Sanofi EVP Specialty Care), CMO David Soergel (ex-Novartis cardiovascular/metabolism development head), CFO Mardi Dier, and a Baker Bros.-anchored board with Chairman Julian C. Baker.

Madrigal Pharmaceuticals firmographics

Firmographics
Name
Madrigal Pharmaceuticals
Legal name
Madrigal Pharmaceuticals, Inc.
Website
https://madrigalpharma.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Madrigal Pharmaceuticals is a biopharmaceutical company developing and commercializing resmetirom (Rezdiffra), the first FDA- and EU-approved oral THR-β agonist for adults with MASH with moderate to advanced liver fibrosis. It sells via a specialty sales force in the U.S. and select EU markets while building a combination MASH pipeline.
Ownership category
akta.pro rank

Madrigal Pharmaceuticals industry classification

Industry
Product category
Specialty Biopharmaceuticals / Metabolic Liver Disease Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAL
Rare Gastroenterology & Hepatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • MASH therapeutics
  • Liver fibrosis treatment
  • Specialty biopharmaceuticals
  • Metabolic disease drugs
  • Thyroid receptor agonist

Where Madrigal Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Conshohocken
HQ country
United States
HQ region
North America

Markets served

Madrigal Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain

Revenue model

  1. Rezdiffra (resmetirom) net product sales: Primary revenue stream from commercial sales of Rezdiffra, the first FDA- and European Commission-approved treatment for MASH with moderate to advanced fibrosis. Full-year 2025 net sales reached $958.4 million, with Q4 2025 net sales of $321.1 million (up 211% YoY) and Q1 2026 net sales of $311.3 million (up 127% YoY). Generated at 93% gross profit margin. Rezdiffra launched in Germany in September 2025 following EU conditional marketing authorization.
  2. MASH pipeline licensing/milestone economics: Future revenue potential from in-licensed pipeline assets including milestone payments and royalties tied to development progress of siRNA programs (Ribo), ARO-PNPLA3 (Arrowhead), ervogastat (Pfizer), and MGL-2086 (CSPC); however, these are primarily expense/investment items rather than near-term revenue.

Pricing tiers

ModelBillingPrice
Unit Pricing—Statutory price transparency disclosures published for Colorado, Connecticut, and Vermont prescribers.

Go-to-market motion4 records

Madrigal Pharmaceuticals product offering

Product offering

Core offering

Madrigal Pharmaceuticals develops and commercializes Rezdiffra (resmetirom), an oral, once-daily, liver-directed small-molecule selective thyroid hormone receptor-beta (THR-β) agonist that is the first U.S. FDA- and European Commission-approved treatment for adults with MASH (formerly NASH) with moderate to advanced liver fibrosis (F2-F3). The company is building a MASH combination-therapy pipeline that layers THR-β agonism with in-licensed mechanisms including siRNA gene-silencing (Arrowhead, Ribo), DGAT-2 inhibition (Pfizer's ervogastat), and oral GLP-1 receptor agonism (CSPC's MGL-2086).

Product overview

Madrigal Pharmaceuticals is a biopharmaceutical company whose commercial offering centers on a single integrated product portfolio anchored by Rezdiffra (resmetirom), the first U.S. FDA- and European Commission-approved oral THR-β agonist treatment for adults with MASH (formerly NASH) with moderate to advanced liver fibrosis. Rezdiffra is the only approved therapy in this indication in both the U.S. and EU and is supported by a layered commercial architecture comprising the Madrigal Patient Support® program (affordability, copay assistance, and education for patients), the Madrigal Medical / Madrigal Medical Affairs platform for healthcare professionals (madrigalmedical.com and the Defuse MASH and Melody education sites), the Taking on Fatty Liver & MASH patient-education site, and the Be Your Liver's #1 Fan awareness campaign. The product is currently positioned as a single approved product plus pipeline, but the company has executed multiple in-licensing deals (ervogastat from Pfizer, ARO-PNPLA3 from Arrowhead, MGL-2086 from CSPC, and six siRNA programs from Ribo/Ribocure) and is actively building a combination-therapy pipeline — including ervogastat/resmetirom, ARO-PNPLA3/resmetirom, MGL-2086/resmetirom, and siRNA/resmetirom combination candidates — designed to be paired with Rezdiffra to address the full spectrum of MASH patient needs.

Differentiator

Problem solved

Functional benefit

Brands

  • Rezdiffra: FDA- and European Commission-approved oral THR-β agonist (resmetirom) for the treatment of MASH with moderate to advanced liver fibrosis; the company's first and only approved product.
  • Madrigal Patient Support
  • Madrigal Corporate Giving

Products and services

  • Rezdiffra (resmetirom) Oral, once-daily, liver-directed, small-molecule selective thyroid hormone receptor-beta (THR-β) agonist. The first U.S. FDA- and European Commission-approved treatment for adults with MASH (formerly NASH) with moderate to advanced liver fibrosis (F2-F3). Approved under accelerated approval based on improvement of MASH and fibrosis. Full-year 2025 net sales reached $958.4 million, generated at 93% gross profit margin.
  • Madrigal Patient Support® Registered-trademark patient support program offering copay assistance, affordability programs for uninsured/underinsured patients, and patient education to support patients on Rezdiffra throughout their treatment journey.

Companies that use Madrigal Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles2 records

Madrigal Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Madrigal Pharmaceuticals partnerships and signals

Strategic signal

Recent moves7 records

Expansion highlights6 records

Madrigal Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Eli Lilly: Pharma incumbent with tirzepatide (Mounjaro/Zepbound) and retatrutide in MASH development; large market cap and commercial scale pose a major competitive threat to Madrigal's specialty positioning.
  • Novo Nordisk: Global diabetes/obesity leader with semaglutide (Wegovy/Ozempic) advancing in MASH Phase 3 (ESSENCE); could reshape standard of care and pressure Rezdiffra positioning with massive commercial reach.
  • Bristol-Myers Squibb: Large-cap pharma with historic hepatology franchise (via Celgene) and ongoing cardiometabolic R&D; comparable specialty-care commercial organization and an experienced international footprint that overlaps Madrigal's launch geographies.

Direct peers

  • 89bio: MASH-focused biopharma developing pegozafermin (FGF21 analog) with Phase 3 ENLIGHTEN program; competes head-to-head with Rezdiffra in moderate-to-advanced MASH fibrosis.
  • Viking Therapeutics: Clinical-stage biopharma developing VK2809, an oral THR-β agonist for MASH in the same mechanism class as resmetirom, plus an oral GLP-1/GIP dual agonist. The closest mechanistic competitor to Madrigal's core asset and pipeline.
  • Akero Therapeutics: Late-stage MASH-focused biopharma developing efruxifermin (FGF21 analog) with Phase 3 HARMONY data; directly competing for share of the F2/F3 MASH market that Rezdiffra currently leads.

Emerging players

  • Inventiva: Late-stage MASH-focused biopharma developing lanifibranor (pan-PPAR agonist); competes in the same F2/F3 MASH regulatory pathway as Rezdiffra.
  • Terns Pharmaceuticals: Developing TERN-501, an oral THR-β agonist for MASH, plus TERN-601 oral GLP-1 — a direct mechanism overlap with both Madrigal's resmetirom and its CSPC-licensed GLP-1 program.

Others

  • Arrowhead Pharmaceuticals: siRNA platform company that licensed ARO-PNPLA3 to Madrigal for combination development; a platform/licensing partner and emerging liver-targeted RNAi competitor.
  • Pfizer: Global pharma that licensed ervogastat (DGAT-2 inhibitor) to Madrigal in January 2026; remains a strategic licensor rather than direct MASH competitor following its exit from primary MASH development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Madrigal Pharmaceuticals social profiles

Digital presence

Madrigal Pharmaceuticals compliance and trust

Trust signal

Compliance3 records

Madrigal Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Madrigal Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles19 records

Madrigal Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Madrigal Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Madrigal Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Madrigal Pharmaceuticals

What does Madrigal Pharmaceuticals do?

Madrigal Pharmaceuticals develops and commercializes Rezdiffra (resmetirom), an oral, once-daily, liver-directed small-molecule selective thyroid hormone receptor-beta (THR-β) agonist that is the first U.S. FDA- and European Commission-approved treatment for adults with MASH (formerly NASH) with moderate to advanced liver fibrosis (F2-F3). The company is building a MASH combination-therapy pipeline that layers THR-β agonism with in-licensed mechanisms including siRNA gene-silencing (Arrowhead, Ribo), DGAT-2 inhibition (Pfizer's ervogastat), and oral GLP-1 receptor agonism (CSPC's MGL-2086).

Is Madrigal Pharmaceuticals a public or private company?

Madrigal Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Madrigal Pharmaceuticals founded?

Madrigal Pharmaceuticals was founded in 2008. It employs 1,001 to 5,000 people.

Where is Madrigal Pharmaceuticals based?

Madrigal Pharmaceuticals is headquartered in Conshohocken, United States, in the North America region.

How does Madrigal Pharmaceuticals make money?

Two revenue lines are on record. Rezdiffra (resmetirom) net product sales are the primary driver. The others are MASH pipeline licensing/milestone economics.

Who are Madrigal Pharmaceuticals's main competitors?

Broad incumbents on record are Eli Lilly, Novo Nordisk and Bristol-Myers Squibb. Direct peers are 89bio, Viking Therapeutics and Akero Therapeutics. Emerging players are Inventiva and Terns Pharmaceuticals. Others are Arrowhead Pharmaceuticals and Pfizer.

Does Madrigal Pharmaceuticals have an API?

No public API is recorded for Madrigal Pharmaceuticals.

What industry is Madrigal Pharmaceuticals in?

Madrigal Pharmaceuticals's product category is Specialty Biopharmaceuticals / Metabolic Liver Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAL, Rare Gastroenterology & Hepatology Disorder Therapies, with a secondary code of HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerSonic Incytes Medical Corp. Announces Multi-Year Partnership With Madrigal Pharmaceuticals, Inc. To Advance Non-Invasive Liver Assessment In MASHSonic Incytes and Madrigal Pharmaceuticals announced a multi-year partnership to advance non-invasive liver assessment for MASH. The collaboration centers on Velacur ONE, an AI-guided ultrasound elastography platform, to improve patient identification and follow-up in gastroenterology, hepatology, and endocrinology settings.Business Wire BlogSonic Incytes Announces Multi-Year Partnership with Madrigal Pharmaceuticals to Advance Non-Invasive Liver Assessment in MASHSonic Incytes and Madrigal Pharmaceuticals announced a multi-year partnership to advance non-invasive liver assessment for metabolic dysfunction-associated steatohepatitis (MASH). The collaboration centers on expanding point-of-care testing, initially in gastroenterology, hepatology, and endocrinology, to address the underdiagnosis of MASH, which affects an estimated 15-20 million U.S. adults.AktienKaplan Fox Reminds Madrigal Pharmaceuticals, Inc. (MDGL) Investors of an Investigation into Potential Securities Law ViolationsKaplan Fox is investigating potential securities violations by Madrigal Pharmaceuticals following a whistleblower complaint filed on October 9, 2026. The complaint alleges retaliation under the Sarbanes-Oxley Act, and Madrigal disputes the allegations. Madrigal's stock fell 8.08% to $396.32 on November 3, 2026.The future of tradingMadrigal Pharmaceuticals grants equity awards to 23 new employeesMadrigal Pharmaceuticals granted equity awards to 23 new non-executive employees on Nov. 1 and Nov. 14, 2026. The awards under the 2025 Inducement Plan included options for 842 shares at $430.36 and 8,296 time-based restricted stock units, with vesting schedules requiring continued employment.FinancialContent Business PageKaplan Fox & Kilsheimer LLP is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law ViolationsKaplan Fox & Kilsheimer LLP is investigating Madrigal Pharmaceuticals for potential securities violations. Madrigal filed a Form 10-Q on November 3, 2026, revealing a whistleblower complaint alleging retaliation under the Sarbanes-Oxley Act. The stock fell 8.08% to $396.32 from $431.16 on November 3.GlobeNewswireKaplan Fox & Kilsheimer LLP is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law ViolationsKaplan Fox & Kilsheimer LLP is investigating Madrigal Pharmaceuticals for potential securities violations. Madrigal filed a Form 10-Q on November 3, 2026, disclosing a whistleblower complaint alleging retaliation under the Sarbanes-Oxley Act. The stock fell 8.08% to $396.32 from $431.16.The future of tradingKaplan Fox & Kilsheimer LLP is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law ViolationsKaplan Fox & Kilsheimer LLP is investigating Madrigal Pharmaceuticals for potential securities violations after a former employee filed a whistleblower complaint alleging retaliation. The complaint seeks damages, and Madrigal disputes the allegations. The stock fell 8.08% to $396.32 on November 3, 2026.AktienKaplan Fox & Kilsheimer LLP Alerts Investors of Madrigal Pharmaceuticals, Inc. (MDGL) to an Investigation of Potential Securities Law ViolationsKaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, following a whistleblower complaint filed on October 9, 2026. The complaint alleges retaliation under the Sarbanes-Oxley Act, and Madrigal disputes the allegations. Madrigal's stock fell 8.08% to $396.32 on November 3, 2026.Business & FinancialMadrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)Madrigal Pharmaceuticals granted inducement awards to new employees on November 1, 2026, including 842 options and 8,296 time-based restricted stock units. The options have an exercise price of $430.36 per share, and all awards vest over four years subject to continued employment.